Solara Active Pharma Sciences has informed that the company (Solara) has successfully completed the inspection carried out by the US Food and Drug Administration (US FDA or Agency) at its Cuddalore facility (Tamil Nadu). The Agency, with its designated investigators, inspected the Cuddalore facility between July 31, 2023 – August 04, 2023. The inspection established that the facility is in an ‘Acceptable State of Compliance’ with Zero Form 483 inspectional observations from the Agency. With this successful inspection outcome, the current inspection classification of Cuddalore site shall be reinstated to NAI (No Action Indicated). The Cuddalore API site is a multi-product facility, caters wide range of APIs to various regulated markets across the globe, including U.S., Europe, Japan and other markets. In this regard, the company has attached a press release.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |